Signatures for both assays include ER, HER2, PR-regulated transcripts, and proliferation-linked genes, which have been very effective in assessing the probability of breast cancer recurrence and classifying patients accordingly into high-, intermediate-, or low-risk groups for recurrence [111]. The gene discussed is ERBB2; the disease is breast carcinoma.